Group 1 - In 2025, the Chinese market showed significant growth, with major stock markets rising sharply and structural opportunities in various sectors, particularly in technology growth stocks, which drove the ChiNext Index up nearly 50% [1] - The period of comprehensive gains for Hong Kong and A-shares was limited to May to September, with declines in other months, notably a drop of over 7% in April due to the "tariff black swan" impact [1] Group 2 - In the private equity market, a subset of products achieved impressive annual returns, with 229 products realizing positive returns for 12 consecutive months in 2025, representing only 4.46% of the total 5139 products [3] - The average cumulative return for these products was 31.83%, with 1006 products from top private equity firms showing performance data, of which 88 had positive returns for 12 months, accounting for 8.75% [3][4] Group 3 - Among the top 20 products with positive returns, 16 were quantitative long products, and 2 were composite strategy products, with 2 products from a hundred billion private equity firm making the list [4] - The product "Square and Peak Zhongzheng 2000 Index Enhanced 21" managed by Square and Investment achieved significant returns, with the highest monthly return in August [6] Group 4 - In the category of private equity firms with assets under 5 billion, only 3.41% of the 4133 products had positive returns for 12 consecutive months, with 141 products achieving this feat [9] - The top 20 products in this category included 13 quantitative long products, with the majority coming from smaller private equity firms [9] Group 5 - The only subjective CTA product to make the list was "Yizu Qinggui Lidong," managed by Yizu Investment, which had a notable cumulative return for 2025 [11] - The product "Hua Nian Jin Qu 2" managed by Hua Nian Private Equity ranked 5th, showcasing strong performance [11] Group 6 - The analysis of excess returns revealed that only 30 out of 802 quantitative long products had positive excess returns for 12 consecutive months, representing 3.74% [12] - The top 10 products in this category were primarily managed by hundred billion private equity firms, with notable performances from firms like Jintong Investment and Ming Stone Fund [12]

Core Viewpoint - In 2025, the Chinese market showed significant growth, with major stock markets rising sharply and structural opportunities in various sectors, particularly in technology growth stocks, which drove the ChiNext Index up nearly 50% [2] Market Performance Summary - The performance of major indices in 2025 included: - Shanghai Composite Index: 18.41% increase in January, with a total of 8.74% in September [3] - ChiNext Index: 49.57% increase in January, but a notable drop of over 7% in April due to external shocks [3] - Shenzhen Component Index: 29.87% increase in January, with fluctuations throughout the year [3] - Hang Seng Index: 27.77% increase in January, with varying monthly performance [3] Private Fund Performance Summary - In the private fund market, 2025 saw a total of 5,139 products with data showing an average cumulative return of 31.83%, with only 229 products (4.46%) achieving positive returns for 12 consecutive months [4] - Among the top-performing private funds, 1,006 products had performance data, with 88 (8.75%) achieving positive returns for 12 consecutive months [4] - The top 20 products in the private fund sector had a threshold for cumulative returns, with a majority being quantitative long products [4] Notable Products and Managers - The "Square and Peak Zhongzheng 2000 Index Enhanced 21" managed by Square and Investment achieved significant returns, with the highest monthly return in August [7] - The "Yizu Qinggui Li Dong" managed by Yizu Investment topped the list among private funds under 5 billion, with substantial returns in March and December [10] - The "Hua Nian Progress 2A" managed by Xue Yuxin ranked fifth, showcasing strong performance [11] Excess Return Analysis - In 2025, 802 quantitative long products had data on excess returns, with only 30 (3.74%) achieving positive excess returns for 12 consecutive months [13] - The top 10 products in terms of cumulative excess returns were managed by firms such as Jintong Investment and Ming Stone Fund [14][16]